Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GMAB | SC 13G | neutral | 4/10 | Darwin Global Management, Ltd. and related entities filed a new Schedule 13G disclosing a 5.9% passive stake in Genmab A | Oct 5, 2026 |
| AYRWF | 6-K | bearish | 6/10 | Ayr Wellness announced the closing of the first transfer of its Ohio operations into wholly-owned subsidiaries of Arbore | Oct 5, 2026 |
| PCVX | 424B5 | neutral | 5/10 | Vaxcyte is offering an undisclosed amount of convertible senior notes due 2032, with a concurrent equity offering of com | Oct 5, 2026 |
| PCVX | 424B5 | bearish | 6/10 | Vaxcyte is conducting a dilutive common stock and pre-funded warrant offering (424B5) concurrently with a convertible no | Oct 5, 2026 |
| ABUS | SC 13D/A | neutral | 4/10 | Roivant Sciences Ltd. filed Amendment No. 14 to its Schedule 13D on Arbutus Biopharma Corp, reporting beneficial ownersh | Oct 5, 2026 |
| ADPT | CLUSTER | neutral | 3/10 | Two senior executives at Adaptive Biotechnologies (Chief People Officer and President/COO) sold a combined ~$390K in ope | Oct 5, 2026 |
| SYRE | PRESS-RELEASE | bearish | 6/10 | Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares at $85.00/share, with an underwriter | Oct 5, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Corcept Therapeutics insiders Sean Maduck and Joseph Lyon sold shares in open-market transactions totaling ~$141K on Oct | Oct 5, 2026 |
| ADIA | 8-K | neutral | 4/10 | Adia Med, Inc. completed the sale of a 30% membership interest in its subsidiary Adia Labs LLC to Live Oak Health LLC (d | Oct 5, 2026 |
| CSTL | 144 | neutral | 4/10 | CEO Derek Maetzold filed a Form 144 notice of intent to sell 28,992 shares of Castle Biosciences common stock, with an e | Oct 5, 2026 |
| ROIV | CLUSTER | bearish | 4/10 | Roivant Sciences insiders executed $7.93M in net selling, dominated by President & Immunovant CEO Eric Venker's open-mar | Oct 5, 2026 |
| VOR | PRESS-RELEASE | neutral | 2/10 | Vor Bio granted stock options and RSUs to 9 newly hired employees as inducement awards under Nasdaq Rule 5635(c)(4). Thi | Oct 5, 2026 |
| MNPR | CLUSTER | bearish | 4/10 | Monopar Therapeutics insiders executed a cluster of non-cash derivative exercises and tax-withholding share surrenders o | Oct 5, 2026 |
| ADRX | SC 13D | neutral | 5/10 | SR One Capital Management, led by Simeon George, filed a Schedule 13D disclosing beneficial ownership of 9,936,661 share | Oct 5, 2026 |
| PPCB | S-1 | bearish | 6/10 | Propanc Biopharma filed an S-1 registration statement for the resale of up to 6,500,000 shares of common stock by Hexsto | Oct 5, 2026 |
| EQ | 8-K | neutral | 3/10 | Equillium received regulatory clearance from Australian authorities (HREC and TGA) to begin a Phase 1 clinical trial of | Oct 5, 2026 |
| IOVA | 8-K | neutral | 4/10 | Iovance Biotherapeutics filed an 8-K to update its corporate presentation, highlighting strong Q2 2026 revenue of ~$99M | Oct 5, 2026 |
| NRXP | 8-K | bullish | 6/10 | NRx Pharmaceuticals' subsidiary, NRx Defense Systems, was awarded an $11.2 million prime contract from DARPA to conduct | Oct 5, 2026 |
| PASG | S-4/A | neutral | 5/10 | Passage Bio filed Amendment No. 3 to its S-4 registration statement for the proposed reverse merger with Remix Therapeut | Oct 5, 2026 |
| UTHR | CLUSTER | bearish | 5/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined ~$818K in open-market sales on October 1-2, 2026. The CEO's sal | Oct 5, 2026 |
| ADIA | 8-K | neutral | 5/10 | Adia Med, Inc. filed a declaratory judgment action in Florida state court seeking to quiet title to 29,059,792 shares (3 | Oct 5, 2026 |
| OSTX | 3 | neutral | 2/10 | Francis Knuettel II, the newly appointed Chief Financial Officer of OS Therapies Inc, filed a Form 3 initial statement o | Oct 5, 2026 |
| OPTH | SC 13G/A | neutral | 3/10 | YA II PN, Ltd. filed an amended Schedule 13G disclosing a 3.0% passive stake (173,000 shares) in Optimi Health Corp. as | Oct 5, 2026 |
| AMLX | 144 | neutral | 3/10 | Director George M. Milne Jr. filed a Form 144 notice of intent to sell 100,000 shares of Amylyx Pharmaceuticals (AMLX), | Oct 5, 2026 |
| PPBT | 6-K | neutral | 2/10 | Purple Biotech announced the appointment of former CEO and current board member Isaac Israel as Interim CEO, effective O | Oct 5, 2026 |
| OSTX | 8-K | neutral | 5/10 | OS Therapies appointed Frank Knuettel II as CFO and Kerry Clem as CCO, replacing outgoing CFO Christopher Acevedo. The p | Oct 5, 2026 |
| USNA | 8-K | neutral | 3/10 | USANA entered into a First Amendment to its existing credit agreement with Bank of America, N.A. and other lenders. The | Oct 5, 2026 |
| FHTX | 3 | neutral | 2/10 | BVF entities (Biotechnology Value Fund, BVF Partners, and affiliates) filed a Form 3 initial statement of beneficial own | Oct 5, 2026 |
| FHTX | SC 13G/A | neutral | 4/10 | Biotechnology Value Fund L.P. (BVF) and affiliated entities filed an amended Schedule 13G on October 5, 2026, reporting | Oct 5, 2026 |
| SYRE | 424B5 | bearish | 5/10 | Spyre Therapeutics filed a preliminary 424B5 prospectus supplement for an underwritten common stock offering of an undis | Oct 5, 2026 |